Compare FBRT & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBRT | CMPX |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | 223 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 701.9M | 927.5M |
| IPO Year | N/A | 2020 |
| Metric | FBRT | CMPX |
|---|---|---|
| Price | $8.51 | $2.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $11.50 | ★ $14.57 |
| AVG Volume (30 Days) | 736.9K | ★ 12.1M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 15.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.34 | N/A |
| Revenue Next Year | $4.95 | $934.41 |
| P/E Ratio | $13.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.24 | $1.61 |
| 52 Week High | $11.84 | $6.88 |
| Indicator | FBRT | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 37.71 | 34.36 |
| Support Level | $8.38 | $1.61 |
| Resistance Level | $9.26 | $3.54 |
| Average True Range (ATR) | 0.21 | 0.14 |
| MACD | -0.06 | 0.13 |
| Stochastic Oscillator | 6.83 | 78.75 |
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. The Company's operations are organized into two business units: (i) Commercial Real Estate Financing, and (ii) Agency Business. Its four reporting segments are as follows: The real estate debt business, The Agency Business, The commercial real estate conduit business, and The real estate owned business.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.